drugset / Trial / NCT04171726

Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation

NCT04171726

Phase 3 Unknown 100 enrolled Erasmus Medical Center Daiichi Sankyo · collab
NaSingle-groupOpen-labelTreatment

Summary

A single-center, investigator-initiated, single arm interventional study in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) in the Erasmus Medical Center in Rotterdam (NL). Study population will be patients undergoing TAVR with no formal indication for oral anticoagulant (OAC) and no dual antiplatelet therapy (DAPT) requirement for coronary stents. Primary endpoint is the incidence of leaflet thickening on MSCT after three months of edoxaban treatment.

Timeline

Start
2019-08-01
Primary completion
2023-06-01
Completion
2023-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule Oral

Indications